维他费林A减轻了 ангиотензин II 诱导的右心室功能障碍和纤维化
Darini Nagarajan1, Vasa Vemuri1, Nicholas Kratholm1
1Department of Physiology, University of Louisville, Louisville, KY 40202, USA.
International journal of molecular sciences
|February 27, 2026
概括
维他费林A (WFA) 逆转右心室 (RV) 功能障碍和由动脉素II (Ang II) 输液引起的纤维化. 这项研究表明WFA.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- ангиотензин II (Ang II) 输液在小鼠中引起心脏功能障碍和缓解症.
- 之前的研究表明,Withaferin A (WFA) 可以减少左心室功能障碍.
- WFA对Ang II诱导的右心室 (RV) 功能障碍的影响尚不清楚.
研究的目的:
- 研究WFA在减轻Ang II诱导的RV功能障碍和重塑中的治疗潜力.
- 为了确定WFA是否可以逆转RV缓解症样病原体.
主要方法:
- 在C57BL/6J小鼠中输入Ang II,以诱导RV功能障碍.
- 心声造影以评估RV的性能和结构.
- 组织病理学检查和qRT-PCR检查纤维化标志物.
主要成果:
- 格II增加了RV壁厚度和降低了缩/放缩功能.
- 格II上调了亲纤维细胞标记物 (TGF-β,纤维蛋白,原).
- 在WFA治疗中恢复了RV功能和减弱的纤维化.
结论:
- WFA减轻了Ang II诱导的RV缓解症类似的重塑和功能障碍.
- WFA证明了对RV的抗纤维和心脏保护作用.
- WFA是心脏缓解症的潜在治疗候选者.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Heart Failure V: Medical Management
419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419


